Loading...
Loading...
Medical Disclaimer: This information is for educational purposes only and is not a substitute for professional medical advice.
Other
Fosphenytoin is a water-soluble prodrug of phenytoin, a hydantoin anticonvulsant used for the short-term treatment and prevention of seizures, including status epilepticus.
Name
Fosphenytoin
Raw Name
FOSPHENYTOIN SODIUM
Category
Other
Salt Form
Sodium
Drug Count
3
Variant Count
16
Last Verified
February 17, 2026
RxCUI
1670195, 1670200, 1670197, 1670201
UNII
7VLR55452Z
About Fosphenytoin
Fosphenytoin is a water-soluble prodrug of phenytoin, a hydantoin anticonvulsant used for the short-term treatment and prevention of seizures, including status epilepticus.
Detailed information about Fosphenytoin
References used for this content
This page is for informational purposes only and does not replace medical advice. Consult a qualified healthcare professional before using any medication containing Fosphenytoin.
Because fosphenytoin is a prodrug, it does not possess significant anticonvulsant activity itself. Instead, once it enters the bloodstream, it is rapidly converted by phosphatase enzymes (enzymes that remove phosphate groups) into active phenytoin. Healthcare providers measure fosphenytoin doses in "Phenytoin Equivalents" (PE) to ensure that the amount of active medication delivered is consistent with standard phenytoin dosing. This medication is strictly intended for short-term use, typically not exceeding five days, as a bridge until the patient can resume oral anticonvulsant therapy.
The therapeutic action of fosphenytoin is entirely dependent on its conversion to phenytoin. At the molecular level, phenytoin acts as a potent stabilizer of neuronal membranes. It achieves this by selectively blocking voltage-gated sodium channels in their inactive state. By binding to these channels, phenytoin prevents the rapid, repetitive firing of action potentials (electrical signals) that characterize a seizure.
Unlike some other sedatives, phenytoin does not cause general central nervous system (CNS) depression; rather, it limits the spread of seizure activity from a focal point to other areas of the brain. It specifically targets the motor cortex, where it inhibits the spread of electrical discharges. This mechanism is crucial for stopping the physical convulsions associated with tonic-clonic seizures. Additionally, phenytoin may influence calcium flux across neuronal membranes and modulate neurotransmitter levels, such as gamma-aminobutyric acid (GABA), though its primary effect remains the modulation of sodium conductance.
Understanding the pharmacokinetics of fosphenytoin is essential for safe clinical administration, particularly regarding its conversion and the subsequent behavior of phenytoin.
Fosphenytoin is FDA-approved for several critical indications where oral administration is not feasible:
Off-label uses sometimes include the management of trigeminal neuralgia (severe facial pain) in acute crisis settings, although this is less common than its use in epilepsy.
Fosphenytoin is available exclusively as an injectable solution for intravenous (IV) or intramuscular (IM) use. It is typically supplied in vials containing 100 mg PE or 500 mg PE (where 1 mg PE is equivalent to 1 mg of phenytoin sodium). Because of the risks associated with rapid administration, it is always administered in a clinical setting under continuous cardiac monitoring.
> Important: Only your healthcare provider can determine if Fosphenytoin is right for your specific condition. This medication is typically reserved for hospital or emergency settings.
Dosing for fosphenytoin is always expressed in milligrams of phenytoin sodium equivalents (mg PE). Healthcare providers must exercise extreme caution to avoid confusion between fosphenytoin and phenytoin sodium doses.
Fosphenytoin is approved for use in pediatric patients, including neonates, for the control of status epilepticus and the prevention of seizures.
In patients with kidney disease, the binding of phenytoin to albumin is often reduced (uremia). This results in a higher fraction of "free" (active) phenytoin in the blood. While the total phenytoin level might appear normal, the free level could be toxic. Healthcare providers may need to adjust doses based on free phenytoin levels rather than total levels.
Since the liver is the primary site of phenytoin metabolism, patients with liver disease are at high risk for toxicity. Doses should be started at the lower end of the range, and frequent monitoring of plasma concentrations is mandatory.
Older adults often have lower albumin levels and decreased hepatic clearance. Healthcare providers typically use more conservative dosing and slower infusion rates to prevent cardiovascular complications and toxicity.
Fosphenytoin is administered only by healthcare professionals in a hospital or clinical setting. It is given as an injection into a large vein (IV) or into a large muscle (IM).
Because fosphenytoin is typically administered in a hospital setting by medical staff, missed doses are rare. If a maintenance dose is delayed, the healthcare provider will administer it as soon as possible. Patients transitioning to oral phenytoin must follow a strict schedule to prevent breakthrough seizures.
Fosphenytoin overdose is essentially a phenytoin overdose. Early signs include nystagmus (involuntary eye movements), ataxia (loss of coordination), and dysarthria (slurred speech). Severe overdose can lead to coma, respiratory depression, and cardiovascular collapse. There is no specific antidote for phenytoin; treatment is supportive, focusing on maintaining airway and cardiovascular stability. Hemodialysis is generally not effective because phenytoin is highly protein-bound.
> Important: Follow your healthcare provider's dosing instructions. Do not adjust your dose without medical guidance.
Side effects of fosphenytoin often occur during or immediately after the infusion. Many are related to the rapid conversion to phenytoin or the infusion rate itself.
> Warning: Stop taking Fosphenytoin and call your doctor immediately if you experience any of these.
While fosphenytoin is intended for short-term use, the phenytoin it produces can cause long-term issues if therapy is continued orally:
Fosphenytoin carries a significant FDA Boxed Warning regarding its cardiovascular risks. The warning emphasizes that the rate of IV administration must not exceed 150 mg PE/min in adults or 2 mg PE/kg/min in pediatric patients. Exceeding these rates is associated with severe hypotension and cardiac arrhythmias. Close monitoring is not just recommended; it is mandatory for patient safety. This warning exists because the rapid introduction of phenytoin into the system can destabilize the heart's electrical conduction system.
Report any unusual symptoms to your healthcare provider immediately.
Fosphenytoin is a potent medication that requires careful management by skilled healthcare professionals. It should only be used in settings where emergency resuscitative equipment and continuous monitoring are available. Because it is a prodrug of phenytoin, all warnings associated with phenytoin also apply to fosphenytoin.
The FDA has issued a Boxed Warning for fosphenytoin due to the risk of severe cardiovascular events. The rate of intravenous fosphenytoin administration should not exceed 150 mg phenytoin sodium equivalents (PE) per minute in adults and 2 mg PE/kg/min (or 150 mg PE/min, whichever is slower) in pediatric patients. Rapid administration is associated with severe hypotension (low blood pressure) and cardiac arrhythmias (irregular heartbeats), including heart block, ventricular fibrillation, and cardiac arrest. Although the risk of cardiovascular toxicity increases with infusion rate, these events can also occur at or below the recommended infusion rates. Continuous electrocardiogram (ECG), blood pressure, and respiratory monitoring are essential during and after the infusion.
Patients receiving fosphenytoin require intensive monitoring:
Fosphenytoin causes significant CNS depression, dizziness, and coordination issues. Patients should not drive or operate heavy machinery until the effects of the drug have completely worn off and their seizure condition is stable.
Alcohol can have complex interactions with fosphenytoin. Acute alcohol intake can increase phenytoin levels (increasing toxicity risk), while chronic alcohol use can decrease phenytoin levels (increasing seizure risk). Patients should avoid alcohol while being treated with this medication.
Abrupt discontinuation of any anticonvulsant, including fosphenytoin/phenytoin, can trigger status epilepticus. If the drug must be stopped, it should be done gradually under medical supervision, unless a severe skin reaction or organ failure necessitates immediate cessation.
> Important: Discuss all your medical conditions with your healthcare provider before starting Fosphenytoin.
For each major interaction, the mechanism usually involves the induction or inhibition of the CYP2C9/2C19 enzymes or displacement from albumin binding sites. Management typically involves dose titration based on clinical response and serum drug level monitoring.
> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking.
Fosphenytoin must NEVER be used in the following circumstances:
Conditions requiring careful risk-benefit analysis include:
Patients who are allergic to carbamazepine or phenobarbital may also be allergic to fosphenytoin. There is a known cross-sensitivity among aromatic anticonvulsants. Healthcare providers must be alert for signs of rash or fever if a patient has a known allergy to these related drugs.
> Important: Your healthcare provider will evaluate your complete medical history before prescribing Fosphenytoin.
Fosphenytoin is classified as having significant risks during pregnancy. It is known to cross the placenta.
Phenytoin is excreted into breast milk in small amounts. While the American Academy of Pediatrics generally considers phenytoin compatible with breastfeeding, the infant should be monitored for signs of sedation or poor feeding. Because fosphenytoin is for short-term acute use, breastfeeding is often temporarily suspended while the mother is in the ICU or emergency setting.
Fosphenytoin is approved for use in pediatric patients of all ages. It is often preferred over IV phenytoin in children because it causes fewer injection site complications (like Purple Glove Syndrome). However, the weight-based dosing and infusion rate limits (2 mg PE/kg/min) must be strictly followed to avoid cardiac toxicity.
Patients over age 65 are at a higher risk for adverse effects.
In patients with end-stage renal disease or significant impairment, the protein binding of phenytoin is altered. Total phenytoin levels can be misleadingly low, while free levels remain high. Dosing should be based on clinical response and free phenytoin levels. Dialysis does not significantly clear phenytoin.
Since the liver metabolizes phenytoin, any degree of hepatic failure increases the risk of toxicity. Patients with a high Child-Pugh score require lower maintenance doses and very close monitoring of blood levels.
> Important: Special populations require individualized medical assessment.
Fosphenytoin is a prodrug that is converted to phenytoin by the action of alkaline phosphatases. The active moiety, phenytoin, acts on voltage-gated sodium channels in the neuronal cell membrane. It specifically binds to and stabilizes the inactive state of the sodium channel, which prevents the influx of sodium ions into the neuron. This action limits the ability of the neuron to fire high-frequency repetitive action potentials, thereby suppressing the spread of seizure activity without interfering with normal low-frequency neuronal firing.
The pharmacodynamic effect of fosphenytoin is identical to that of phenytoin once conversion has occurred. The onset of action for stopping status epilepticus is typically within 10 to 20 minutes after the start of an IV infusion. The duration of effect is long, matching the half-life of phenytoin (approx. 22 hours), which allows for once- or twice-daily dosing after the initial loading phase.
| Parameter | Value |
|---|---|
| Bioavailability | 100% (IV and IM) |
| Protein Binding | 95-99% (Fosphenytoin); 90% (Phenytoin) |
| Half-life (Conversion) | 8-15 minutes |
| Half-life (Phenytoin) | 22 hours (average, non-linear) |
| Tmax (Phenytoin after IM) | 3 hours |
| Metabolism | Hepatic (CYP2C9, CYP2C19) |
| Excretion | Renal (<5% unchanged) |
Fosphenytoin is classified as a hydantoin anticonvulsant. It is unique within this class as a parenteral prodrug. Related medications include phenytoin (the active form) and ethotoin (an oral hydantoin). It is often grouped with other "first-line" status epilepticus medications like lorazepam, midazolam, and levetiracetam.
Medications containing this ingredient
Common questions about Fosphenytoin
Fosphenytoin is primarily used in emergency medical settings to treat status epilepticus, which is a state of continuous, life-threatening seizures. It is also used to prevent and treat seizures that may occur during or after neurosurgery when a patient cannot take oral medications. Because it is a prodrug of phenytoin, it provides the same anticonvulsant benefits but is much safer for the veins and heart when given as an injection. It is intended only for short-term use, usually for five days or less. Your doctor will typically transition you to an oral seizure medication as soon as you are stable enough to swallow.
The most common side effects include nystagmus (involuntary eye movements), dizziness, sleepiness, and loss of coordination (ataxia). A very specific side effect of fosphenytoin is a temporary sensation of itching, burning, or tingling, especially in the groin area or face, which usually happens during the infusion. Some patients may also experience nausea, vomiting, or a ringing in the ears. Most of these effects are temporary and resolve once the infusion is finished. However, medical staff will monitor you closely to ensure these symptoms do not become severe.
Alcohol should be strictly avoided while being treated with fosphenytoin or its active form, phenytoin. Acute alcohol consumption can slow down the metabolism of the drug, leading to dangerously high levels and increased toxicity. Conversely, chronic or heavy alcohol use can speed up the metabolism, causing the drug levels to drop and increasing the risk of a breakthrough seizure. Alcohol also increases the sedative effects of the medication, which can lead to severe drowsiness or respiratory issues. Always discuss your alcohol history with your healthcare provider before receiving this treatment.
Fosphenytoin is generally not considered safe during pregnancy unless it is a life-saving emergency. The active form, phenytoin, is known to cause 'Fetal Hydantoin Syndrome,' which can result in birth defects like cleft palate, heart problems, and limb abnormalities. It can also cause a dangerous bleeding disorder in newborns by interfering with Vitamin K. However, because status epilepticus can be fatal for both the mother and the baby, doctors may still use it if other treatments fail. If you are pregnant or planning to become pregnant, your doctor will weigh these significant risks against the necessity of seizure control.
When given intravenously for status epilepticus, fosphenytoin begins to work as it is converted into phenytoin in the blood. This conversion process takes about 8 to 15 minutes. Most patients will see a reduction or cessation of seizure activity within 10 to 20 minutes after the start of the infusion. If given by intramuscular injection, it takes longer to reach peak levels in the brain, usually around 30 minutes to 3 hours. Because of this delay, the intramuscular route is not used for life-threatening emergencies where immediate seizure control is required.
No, you should never stop taking fosphenytoin or any anticonvulsant suddenly. Abruptly stopping the medication can cause 'rebound' seizures or trigger status epilepticus, which is a continuous seizure state that is a medical emergency. If the medication needs to be discontinued, a healthcare provider will gradually taper the dose while starting another seizure medication. The only exception is if you develop a life-threatening allergic reaction or skin rash, in which case your doctor will stop the drug immediately and provide alternative emergency care.
Since fosphenytoin is administered by healthcare professionals in a hospital setting, it is very unlikely that a dose will be missed. The medical staff follows a strict schedule to maintain therapeutic levels in your blood. If you are being transitioned to oral phenytoin at home and you miss a dose, you should contact your doctor immediately. Generally, if it is within a few hours of the scheduled time, you may be told to take the missed dose, but if it is almost time for the next one, you should skip it. Never double the dose to make up for a missed one.
Weight gain is not a typical side effect of fosphenytoin, especially since it is only used for a short duration (usually less than five days). Long-term use of the active form, phenytoin, is also not strongly associated with weight gain, unlike some other seizure medications like valproic acid or gabapentin. If you notice sudden weight gain or swelling while in the hospital, it is more likely related to IV fluids or other medical conditions. Always report any sudden changes in your weight or physical appearance to your medical team.
Fosphenytoin has many significant drug interactions because it affects the liver enzymes that break down other medicines. It can make some drugs, like birth control pills or blood thinners, less effective. Other drugs, like certain antibiotics or heart medications, can cause fosphenytoin levels to rise to toxic levels. Because of these complexities, it is vital that you tell your healthcare provider about every medication, supplement, and herbal product you are taking. Your doctor will monitor your blood levels closely to ensure all your medications are working safely together.
Yes, fosphenytoin sodium is available as a generic medication. The brand name version, Cerebyx, is also available, but the generic version is widely used in hospitals to reduce costs. Both the brand and generic versions are considered bioequivalent, meaning they work the same way in the body. Since it is an injectable medication used primarily in emergency or surgical settings, the choice between brand and generic is typically made by the hospital pharmacy rather than the patient.